BREAKING! H5N1 Strains Emerging In Cows Possess New Mutation NA-T438I Associated With Reduced Susceptibility To Neuraminidase Inhibitors!
Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 28, 2024 7 months, 3 weeks, 4 days, 8 hours, 6 minutes ago
H5N1 News: While the U.S. CDC is still insisting that many of the antivirals it has in its stockpile such as Oseltamivir (Tamiflu) and Baloxavir marboxil, sold under the brand name Xofluza are effective against the current H5N1 strains in circulation, there are many incidences elsewhere globally where situations have shown that these drugs no longer work against the all the new H5N1 strains that have been in circulation in the last 18 months.
H5N1 Strains Emerging In Cows Possess New Mutation NA-T438I
Associated With Reduced Susceptibility To Neuraminidase Inhibitors
For instance, in the reported deaths in various past
H5N1 News coverages of individuals infected with H5N1 in Cambodia, Vietnam and Chile, it was found that the administration of both Tamiflu and Xofluza did not prevent the resulting deaths in these individuals even when treatment with the said antivirals started in the initial stages.
We can still see mistakes that were made in the COVID-19 pandemic still being made in the preparations for the impending H5N1 outbreak. Instead of spending monies, resources and time into developing a combo of effective and safe antivirals to combat H5N1, governments are once again funding mRNA vaccine developments with the same players in the pharma industry and in some cases also spending monies on monoclonal therapeutics research.
Instead of moving away from antibody-based prophylactics or therapeutics that are known to induce the virus to mutate even further, many are still doing the same mistake of simply focusing on vaccines and monoclonal drugs.
U.S. CDC Finds Mutation In H5N1 Virus That Shows the Virus Is Evolving And Developing Resistance To Neuraminidase Inhibitors
In a recent updated report by the U.S. CDC, it was reported that researchers had indeed found a mutation on one virus sequence from cows that showed reduced susceptibility to present neuraminidase inhibitors.
https://www.cdc.gov/flu/avianflu/spotlights/2023-2024/avian-situation-update.htm
The new H5N1 mutation NA-T438I worryingly indicates that the virus is indeed evolving towards a direction of drug resistance towards known neuraminidase inhibitors.
Research On New Drugs Are Bring Up The Worse Drug Candidates!
There are some ongoing researches by certain scientist who are being over-zealous and adamant that their identified candidates are suitable to prevent or treat H5N1 infections despite not looking at the total macro perspective as to how three quarters of the global population have been already exposed to either the SARS-CoV-2 virus or the COVID-19 mRNA vaccines and how these are affecting their immunity systems and other organs!
Hence, without wanting to go into details, some of these compounds like neomycin, galactans are simply going to backfire!
/>
A Multiprong Drug Candidate Needed
Thailand Medical News strongly recommends that H5N1 prophylactic and therapeutics being developed should encompass a variety of compounds that act as neuraminidase and hemagglutin Inhibitors plus M2 ion channel inhibitors. Also including targeting the ribonucleoprotein would help create a real efficient broadspecturm antiviral. Simply targeting one component of the H5N1 virus is not going to help.
Avian Influenza A viruses are known to evolve and mutate rapidly, though not at the rate of the current SARS-CoV-2 viruses, they do so more efficiently against known antiviral compounds!
We also urge readers and journalists to do more investigations into the reported case of a farm hand had who got infected in Texas and was claimed to have been treated and also recovered!
For the latest H5N1 News, keep on logging to Thailand Medical News.
Share
Tweet
Share
